Enterprise Value

293.5B

Cash

6.378B

Avg Qtr Burn

N/A

Short % of Float

0.62%

Insider Ownership

0.09%

Institutional Own.

77.65%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Update

GARDASIL 9 Details
Human Papillomavirus 9-valent Vaccine, Human papillomavirus

Approved

Update

Approved

Update

KEYTRUDA Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Approved

Update

PREVYMIS™ (letermovir) Details
Cytomegalovirus, Viral infection

Approved

Quarterly sales

TUKYSA (Tucatinib) Details
Solid tumor/s, Colorectal cancer , Cancer, Metastatic colorectal cancer

Approved

Quarterly sales

LYNPARZA(olaparib) + abi/pred Details
Solid tumor/s, Cancer, Castration-resistant prostate cancer

Approved

Quarterly sales

KEYTRUDA in comb w/chemotherapy Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Approved

Quarterly sales

KEYTRUDA+ chemotherapy Details
Cancer, Biliary Tract Cancer

Approved

Quarterly sales

KEYTRUDA+ trastuzumab+ chemotherapy Details
Cancer, Gastroesophageal adenocarcinomas, Gastric cancer

Approved

Quarterly sales

Approved

Quarterly sales

KEYTRUDA+ chemotherapy Details
Cancer, Gastroesophageal adenocarcinomas, Gastric cancer

Approved

Quarterly sales

Sotatercept Details
Pulmonary arterial hypertension

PDUFA

Approval decision

PDUFA

Approval decision

PDUFA

Approval decision

PDUFA

Approval decision

Bomedemstat Details
Thrombocythemia

Phase 3

Data readout

KEYTRUDA+pemetrexed Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Phase 3

Data readout

KEYTRUDA +carboplatin + paclitaxel Details
Solid tumor/s, Cancer, Carcinoma , Endometrial cancer

Phase 3

Data readout

Phase 3

Data readout

MK-0616 Details
Cardiovascular disease , Hypercholesterolemia

Phase 3

Data readout

Islatravir+ Doravirine Details
Viral infection, Human immunodeficiency virus

Phase 3

Data readout

LAGEVRIO™ (molnupiravir) Details
Viral infection, COVID-19

Phase 3

Data readout

KEYTRUDA Details
Solid tumor/s, Cancer, Urothelial carcinoma

Phase 3

Update

KEYTRUDA +LENVIMA® (lenvatinib) Details
Cancer, Non-small cell lung carcinoma

Phase 3

Update

KEYTRUDA+ chemotherapy Details
Cancer, Mesothelioma, Malignant pleural/peritoneal mesothelioma

Phase 3

Update

KEYTRUDA + LENVIMA Details
Renal cell carcinoma, Cancer

Phase 3

Update

V116 Details
Pneumococcal Conjugate Vaccine

Phase 3

Update

KEYTRUDA Details
Solid tumor/s, Cancer, ER+/HER2- breast cancer

Phase 3

Update

KEYTRUDA Details
Renal cell carcinoma, Cancer

Phase 3

Update

KEYTRUDA +LENVIMA® (lenvatinib) Details
Cancer, Carcinoma , Endometrial cancer

Phase 3

Update

Phase 3

Initiation

MK-0616 Details
Hypercholesterolemia

Phase 3

Initiation

Efinopegdutide (MK-6024) Details
Non-Alcoholic Fatty Liver Disease, Liver disease

Phase 2b

Initiation

Phase 2

Data readout

PRA023 (Anti-TL1A mAb) Copy Details
Autoimmune disease, Systemic sclerosis

Phase 2

Data readout

PRA023 (Anti-TL1A mAb) Details
Systemic sclerosis, Autoimmune disease

Phase 2

Data readout

Belzutifan + cabozantinib Details
Cancer, Renal cell carcinoma

Phase 2

Update

MK-7240 (PRA023) (Anti-TL1A mAb) Details
Irritable bowel syndrome, Crohns disease, Ulcerative colitis

Phase 2

Update

PRA052 Details
Inflammatory bowel disease

Phase 1

Data readout

KEYTRUDA + LENVIMA Details
Cancer, Head and neck squamous cell carcinoma

Failed

Discontinued

KEYTRUDA+ enzalutamide + androgen deprivation therapy (ADT) Details
Solid tumor/s, Cancer, Castration-resistant prostate cancer

Failed

Discontinued